Immune Changes in Patients with Colorectal Cancer Treated by Adjuvant Therapy with Monoclonal Antibody 17-1 A: A Pilot Study

REFERENCES

• Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993; 29A: 2077–2079.
   PubMed Web of Science ®Google Scholar
• Punt CJA. New drugs in the treatment of colorectal car-cinoma. Cancer 1998; 83: 679–689.
   PubMed Web of Science ®Google Scholar
• Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994; 125: 437–446.
   PubMed Web of Science ®Google Scholar
• Li W, Berencsi K, Basak S et al. Human colorectal can-cer (CRC) antigen C017-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. J Immunol 1997; 159: 763–769.
   Google Scholar
• Herlyn DM, Steplewski Z, Herlyn MF, Kopowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980; 40: 717–721.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001; 40: 17–24.
   PubMed Web of Science ®Google Scholar
• Riethmuller G, Holz E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 1788–1794.
   Google Scholar
• Punt CJA, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and follinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002; 360: 671–677.
   Google Scholar
• Flieger D, Spengler U, Beier I et al. Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combina-tion of cytokines. Hybridoma 1999; 18: 63–68.
   Google Scholar
• Hjelm Skog A, Ragnhammar P, Fagerberg J et al. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and inter-leukin-2 for treatment of patients with advanced colorectal car-cinoma. Cancer Immunol Immunother 1999; 48: 463–470.
   Google Scholar
• Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cel-lular immune response against a colorectal carcinoma-associat-ed antigen in patients. Proc Natl Acad Sci USA 1995; 92: 4773–4777.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas JF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Tumor specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000; 164: 3902-3912.
   Google Scholar
• Baxevanis CN, Tsavaris NB, Papadhimitriou SI et al. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumors receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer 1997; 33: 1202-1208.
   Google Scholar
• Baxevanis CN, Papilas K, Dedoussis GVZ, Pavlis T, Papamichail M. Abnormal cytokine levels correlate with impaired cellular immune responses after surgery. Clin Immunol Immunopathol 1994; 71: 82–88.
   PubMedGoogle Scholar
• Pawelec G, Rees RC, Kiessling R et al. Cells and cytokines in immunotherapy and gene therapy of cancer. Crit Rev Oncogenesis 1999; 10: 83–127.
   PubMed Web of Science ®Google Scholar
• Haller DG. An overview of adjuvant therapy for col-orectal cancer. Eur J Cancer 1995; 31: 1255–1263.
   Google Scholar
• Adkins JC, Spencer CN. Edrecolomab (monoclonal antibody 17-1A). Drugs 1998; 56: 619–628.
   PubMed Web of Science ®Google Scholar
• Reali E, Guilani AL, Spisani S et al. Interferon-? enhances monoclonal antibody 17-1A-dependent neutrophil cytotoxicity toward colorectal carcinoma cell line SW11-16. Clin Immunol Immunopathol 1994; 71: 105–112.
   Google Scholar
• Nakayama Y, Shibao K, Sako T et al. Serum levels of interleukin-12 in patients with gastrointestinal cancer. Anticancer Res 2000; 20: 635–640.
   Google Scholar
• Elsasser-Beile U, Kolble N, Grussenmeyer T, Wetterauer U, Schuttze-Seemann W. Correlation of clinical and immunological parameters of metastatic renal cell carcino-ma patients undergoing therapy with interleukin-2, interferon-alpha and retinoic acid. Anticancer Res 1998; 18: 1883-1890.
   Google Scholar
• Chen YM, Ting CC, Pang JW et al. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs interleukin-2. J Interferon Cytokine Res 2000; 20: 31–39.
   Google Scholar
• Bungard S, Flieger D, Schweitzer S, Sauerbruch T, Spengler U. The combination of interleukin-2 and interferon-a effectively augments the antibody-dependent cellular cytotoxic-ity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29. Cancer Immunol Immunother 1998; 46: 213–220.
   PubMed Web of Science ®Google Scholar
• Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt-Wolf I. Combinations of the cytokines IL-12, IL-2 and IFN-a significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2. Cytokine 2000; 12: 756–761.
   PubMed Web of Science ®Google Scholar
• Gosselin J, Tomolu A, Gallo RC, Flamand L. Interleukin-15 as an activator of natural killer cell-mediated antiviral response. Blood 1999; 94: 4210-4219.
   Google Scholar
• Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt-Wolf IC. Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotox-icity of monoclonal antibody 17-1A. Z Gastroenterol 2000; 38: 615–622.
   PubMed Web of Science ®Google Scholar
• Stetye J, Ragnhammar P, Liljefors M et al. Immunopathology of metastases in patients of colorectal carci-noma treated with monoclonal antibody 17-1A and granulo-cyte-macrophage colony-stimulating factor. Clin Cancer Res 1998; 4: 1921–1929.
   Google Scholar
• Deehan DJ, Heys SD, Simpson WC, Broom J, Franks C, Eremin O. In vivo cytokine production and recombinant interleukin-2 immunotherapy: an insight into the possible mechanisms underlying clinical responses. Br J Cancer 1994; 69: 1130–1135.
   PubMed Web of Science ®Google Scholar
• Flieger D, Hoff AS, Sauerbruch T, Schmidt-Wolf IGH. Influences of cytokines, monoclonal antibodies and chemother-apeutic drugs on epithelial cell adhesion molecule (EpCAM) and Lewis'' antigen expression. Clin Exp Immunol 2001; 123: 9–14.
   PubMed Web of Science ®Google Scholar
• Meyaard L, van der Vuurst de Vries AR, de Ruiter T, Lanier LL, Phillips JH, Clevers H. The epithelial cellular adhe-sion molecule (Ep-CAM) is a ligand for the leukocyte-associat-ed immunoglobulin-like receptor (LAIR). J Exp Med 2001; 194: 107–112.
   Google Scholar